Epithelial ovarian cancer

被引:30
作者
Hensley M.L. [1 ]
机构
[1] Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, 10021, NY
关键词
Carboplatin; Clin Oncol; Epithelial Ovarian Cancer; Ovarian Cancer; Paclitaxel;
D O I
10.1007/s11864-002-0059-3
中图分类号
学科分类号
摘要
Epithelial ovarian cancer is the most lethal of all gynecologic malignancies. Most women have advanced stage disease. Access to appropriate initial surgical management by a gynecologic oncologist is important because treatment and survival are affected by appropriate surgical staging and debulking of tumor. After debulking/ staging surgery, chemotherapy with platinum-taxane-based regimens is appropriate for most patients. Patients with early stage, low-risk tumors may be cured with surgery alone. Interval cytoreductive surgery may be appropriate for patients who are initially suboptimally cytoreduced and are stable or responding to chemotherapy. The role of second-look surgery remains to be defined. Patients with recurrent or relapsed ovarian cancer are incurable. There are several chemotherapy agents that can achieve disease responses, which may be associated with palliation of tumor-related symptoms. Participation in clinical trials is encouraged for all patients. Novel approaches to managing minimal residual disease are being tested in hopes of decreasing the number of patients who relapse after achieving complete clinical remission. © 2002, Current Science Inc.
引用
收藏
页码:131 / 141
页数:10
相关论文
共 57 条
[1]  
Landis S.H., Murray T., Bolden S., Wingo P.A., Cancer statistics, 1999, CA Cancer J Clin, 49, pp. 8-31, (1999)
[2]  
Young R.C., Walton L.A., Ellenberg S.S., Et al., Adjuvant therapy in stage I and II epithelial ovarian cancer. Results of two prospective randomized trials, N Engl J Med, 322, pp. 1021-1027, (1990)
[3]  
Hoskins W.J., McGuire W.P., Brady M.F., Et al., The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma, Am J Obstet Gynecol, 170, pp. 974-979, (1994)
[4]  
Bonnefoi H., A'Hern R.P., Fisher C., Et al., Natural history of stage IV epithelial ovarian cancer, J Clin Oncol, 17, pp. 767-775, (1999)
[5]  
McGuire W.P., Hoskins W.J., Brady M.F., Et al., Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N Engl J Med, 334, pp. 1-6, (1996)
[6]  
Ford D., Easton D.F., Bishop D.T., Et al., Risk of cancer in BRCA1-mutation carriers, Lancet, 343, pp. 692-695, (1994)
[7]  
Burke W., Daly M., Garber J., Et al., Recommendations for follow-up and care of individuals with inherited predisposition to cancer, II: BRCA1 and BRCA2. Cancer Genetics Studies Consortium, JAMA, 277, pp. 997-1003, (1997)
[8]  
Ozols R.F., Morgan R.J., Copeland L., Et al., Update of the NCCN ovarian cancer practice guidelines, Oncology, 11, pp. 95-105, (1997)
[9]  
McGowan L., Lesher L.P., Norris H.J., Barnett M., Mis-staging of ovarian cancer, Obstet Gynecol, 65, pp. 568-572, (1985)
[10]  
van der Burg M.E.L., van Lent M., Buyse M., Et al., The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer, N Engl J Med, 332, pp. 629-634, (1995)